Precision Biosciences Stock News

Northern Trust Corp lifted its stake in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 6.2% in the second quarter, Holdings Channel reports. The institutional investor owned 525,808 shares of the companys stock after buying an additional 30,617 shares during the quarter. Northern Trust Corps holdings in Precision BioSciences were worth $6,582,000 as of its most []

CRISPR Therapeutics (CRSP) receives clearance from Health Canada to initiate clinical studies for VCTX210, its investigational therapy for the treatment of type 1 diabetes.

The average of price targets set by Wall Street analysts indicates a potential upside of 98% in Precision BioSciences (DTIL). While the effectiveness of this highly sought-after metric is questionable

The average of price targets set by Wall Street analysts indicates a potential upside of 98% in Precision BioSciences (DTIL). While the effectiveness of this highly sought-after metric is questionable

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 68.33% and 181.35%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st

Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors need to know before the announcement.

DTIL has developed its own proprietary genome editing technology, ARCUS, with the potential to deliver safer therapies compared to other more common genome editing technologies.

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® gen

Precision BioSciences Inc (NASDAQ: DTIL) and iECURE announced a license and collaboration agreement. Under the agreement iECURE plans to advance Precision's PBGENE-PCSK9 candidate into Phase 1 studi

DURHAM, N.C. & PHILADELPHIA--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with

Precision (DTIL) signs an exclusive license agreement with Tiziana to explore the latter's fully human anti-CD3 mAb, foralumab, for treating various cancer indications. Stock up.

The stock price of Precision BioSciences Inc (NASDAQ: DTIL) increased by over 4% during intraday trading. This is why it happened.

Shares in Tiziana Life Sciences PLC raced 20% higher in the opening minutes of trading on Wall Street after the group inked an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL). T

Precision BioSciences Inc (NASDAQ: DTIL) and Tiziana Life Sciences plc (NASDAQ: TLSA) have announced an exclusive license agreement for Tiziana's foralumab. The companies plan to explore the full

Tiziana Life Sciences PLC surged 19% to 73p after signing an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL). The pair will explore the use of Tiziana's foralumab monoclonal ant